EUVIMEDEUVIMED entdecken
Editorial

Felzartamab and Antibody-Mediated Rejection in Kidney Transplants — Hope at Last?

Julie R Ingelfinger, Winfred W Williams

New England Journal of Medicine · 2024

DOI: 10.1056/nejme2407009 ↗

Kurz gefasst

Editorial in der Zeitschrift New England Journal of Medicine, 2024. Verfasst von Julie R Ingelfinger und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Graft Rejection, Kidney Transplantation, Immunologic Factors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedGraft RejectionKidney TransplantationImmunologic FactorsHumansImmunosuppressive AgentsClinical Trials as Topic

Substanzen

Antibodies, Monoclonal, HumanizedImmunosuppressive AgentsfelzartamabImmunologic Factors

Zitieren

APA

Ingelfinger, J. R., & Williams, W. W. (2024). Felzartamab and Antibody-Mediated Rejection in Kidney Transplants — Hope at Last?. New England Journal of Medicine. https://doi.org/10.1056/nejme2407009

Vancouver

Ingelfinger JR, Williams WW. Felzartamab and Antibody-Mediated Rejection in Kidney Transplants — Hope at Last?. New England Journal of Medicine. 2024. doi:10.1056/nejme2407009

BibTeX
@article{Ingelfinger2024,
  author = {Ingelfinger, Julie R and Williams, Winfred W},
  title = {Felzartamab and Antibody-Mediated Rejection in Kidney Transplants — Hope at Last?},
  journal = {New England Journal of Medicine},
  year = {2024},
  doi = {10.1056/nejme2407009}
}
Kostenlos starten →